ExonHit Therapeutics Inc. Receives € 1.93 Million from OSEO Within the Personalized Medicine TEDAC Project in Cancer

Published: Jun 05, 2012

PARIS--(BUSINESS WIRE)--Regulatory News: Exonhit (Paris: ALEHT) announced today that it has been granted € 1,928,000 by OSEO, as part of its involvement in a consortium led by ERYTECH Pharma and funded under the program for "Strategic Industrial Innovation". € 1,126,000 were paid to Exonhit at the inception of the project during the first semester of 2012.

Back to news